Herpes simplex - I-Herpes Simplex
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Herpes simplex emlonyeni.
I-Herpes Simplex (Herpes simplex) ― Usulelo lweHerpes simplex kwiminwe luxhaphake kakhulu kubantwana abancinci kunabantu abadala.
References
Usulelo lwe-HSV-1 luqhubela phambili ngosulelo oluphambili lweeseli ze-epithelial, ezilandelwa yi-latency, ngokukodwa kwi-neurons, kunye nokuphinda kusebenze. I-HSV-1 idla ngokubangela ugqabhuko-dubulo lwe-vesicular, ingakumbi emlonyeni nakwi-genital mucosa. Ukubonakaliswa kwayo ukusuka kwi-herpes ye-orolabial ukuya kwiimeko ezahlukeneyo ezifana ne-herpetic folliculitis, izifo zesikhumba, ukubandakanyeka kwe-ocular, kunye neemeko ezinzima ezifana ne-herpes encephalitis. Unyango lwe-Antiviral lunceda ukulawula usulelo lwe-HSV.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 2 (HSV-2) lusulelo oluxhaphakileyo, oluchaphazela malunga ne-22% yabantu abadala abaneminyaka eyi-12 nangaphezulu, bebonke abantu abadala abazizigidi ezingama-45 e-United States. Ngelixa i-HSV-1 ibangela izilonda zomlomo, inokukhokelela kwizilonda zesini. Nangona kunjalo, xa izigulane zinezilonda kumalungu angasese, i-HSV-2 idla ngokuba yeyona nto ixhalabisayo. Iimpawu zokuqhambuka kwe-HSV-2 zihlala zingacacanga, njengokurhawuzelelwa kwamalungu angasese kunye nokucaphuka, ezinokulibazisa ukuxilongwa kunye nonyango. Oku kulibaziseka kunokubangela ukosuleleka ngakumbi kubantu abangosulelwanga.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus (HSV) ngokuqhelekileyo kubangela usulelo olufana ne-herpes yangasese kunye nezilonda ezibandayo kulutsha nakubantu abadala. Xa i-HSV yosulela usana kwiiveki ezi-4-6 zokuqala zobomi, oko kunokubangela isigulo esinzima esineziphumo ezibi. Ukuxilonga ngokukhawuleza usulelo lwe-HSV yosana kubalulekile ukunqanda isifo ukuba singabi mandundu, ukuthintela imiba yemithambo-luvo (nokufa) .
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex usulelo luxhaphake kakhulu kwaye lunosulelo olusuka kwabasetyhini abakhulelweyo lusiya kubantwana babo. Le ntsholongwane inokubangela iingxaki ezinzulu zempilo okanye nokufa kwiintsana ezisanda kuzalwa. Nangona kunqabile ngexesha lokukhulelwa ngokwalo, kaninzi kwenzeka ngexesha lokubeleka. Umngcipheko uphezulu ukuba umama wosuleleka kumanqanaba okugqibela okukhulelwa. Nangona kunjalo, lo mngcipheko unokuncitshiswa ngokusebenzisa amachiza e-antiviral okanye ukhethe i-C-section kwiimeko ezithile.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Herpes simplex virus (HSV) uhlobo loku-1 kunye no-2 losulela abantu abaninzi kwihlabathi liphela. Ngokuqhelekileyo, intsholongwane ihlala izolile kwiiseli zemithambo-luvo emva kokosulela ulusu, kodwa inokuphinda isebenze kamva, ibangele izilonda ezibandayo. Ngamanye amaxesha, kukhokelela kwiingxaki ezinzima ezifana nosulelo lwamehlo, ukudumba kwengqondo, okanye iimeko eziyingozi kwiintsana ezisanda kuzalwa kunye nabantu abanamajoni omzimba abuthathaka. Ngelixa amayeza angoku enceda ukulawula usulelo, umngcipheko wokunganyangeki ngamachiza kunye neziphumo ebezingalindelekanga zihlala ziyinkxalabo. Sifuna amachiza amatsha ukujolisa intsholongwane ngcono.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Kukho iindidi ezimbini ze i-herpes simplex (herpes simplex) virus, uhlobo 1 (HSV-1) kunye nohlobo 2 (HSV-2). I-HSV-1 idla ngokubangela usulelo emlonyeni ngelixa i-HSV-2 idla ngokubangela usulelo kumalungu obuni. Zidluliselwa ngokudibana ngqo nomntu osulelekileyo. I-herpes ye-Genital ihlelwa njengesifo esithathelwana ngesondo. Isenokusasazeka kwimveku ngexesha lokubeleka. Emva kosulelo, iintsholongwane zihanjiswa ngemithambo-luvo ukuya kwimizimba yeeseli zemithambo-luvo, apho zihlala ubomi bonke. Iimbangela zokuphindaphinda zingabandakanya: ukunciphisa ukusebenza komzimba, uxinzelelo, kunye nokukhanya kwelanga.
Kwiimeko ezininzi, amayeza e-antiviral athathwa kuphela xa iimpawu zinzima. Iyeza lemihla ngemihla leeantiviral lisenokunikwa umntu owosuleleka rhoqo. Akukho sitofu sokugonya esikhoyo kwaye isitofu sokugonya i-shingles asithinteli i-herpes simplex. Unyango ngamayeza e-antiviral afana ne-aciclovir okanye i-valaciclovir inokwehlisa ubunzima beempawu.
Amazinga ehlabathi jikelele e-HSV-1 okanye i-HSV-2 aphakathi kwama-60% kunye nama-95% kubantu abadala. I-HSV-1 idla ngokusuleleka ngexesha lobuntwana. Kuqikelelwa ukuba i-536 yezigidi zabantu kwihlabathi jikelele (i-16% yabemi) bosulelwe yi-HSV-2 ukususela ngo-2003 ngamaqondo aphezulu phakathi kwabasetyhini kunye nabo bakwilizwe elikhulayo. Uninzi lwabantu abane-HSV-2 abaqondi ukuba bosulelekile.
○ Unyango ― OTC Amachiza
Kuphephe naluphi na ukudibana komzimba, njengokuncamisa umntwana, ngelixa amadyunguza ekhona, njengoko ukudibana kunokusasaza usulelo kwabanye abantu. Kufuneka uphumle ngaphandle kokusela utywala.
#Acyclovir cream